Talphera (NASDAQ:TLPH) Issues Quarterly Earnings Results, Meets Estimates

Talphera (NASDAQ:TLPH) announced its earnings results on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06), FiscalAI reports.

Talphera Price Performance

Talphera stock traded up $0.02 during mid-day trading on Friday, hitting $1.23. The company’s stock had a trading volume of 341,723 shares, compared to its average volume of 278,162. The business has a 50 day moving average price of $1.19 and a 200-day moving average price of $0.96. Talphera has a 12 month low of $0.40 and a 12 month high of $1.57. The stock has a market cap of $63.84 million, a price-to-earnings ratio of -4.56 and a beta of 0.69.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Group One Trading LLC boosted its holdings in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after acquiring an additional 29,500 shares during the period. Virtu Financial LLC purchased a new position in Talphera in the 3rd quarter worth approximately $29,000. Persistent Asset Partners Ltd purchased a new position in Talphera in the 4th quarter worth approximately $42,000. Mariner LLC lifted its position in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in Talphera in the third quarter valued at approximately $89,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TLPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Talphera in a research report on Thursday. Westpark Capital began coverage on Talphera in a report on Thursday, April 30th. They set a “buy” rating and a $3.00 price objective on the stock. Wall Street Zen upgraded Talphera to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research raised Talphera to a “hold” rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.